About BSV
BSV is a Mankind Group Company. Our mission at BSV is to preserve, protect, and enhance quality of life while we remain committed to ‘Bringing Life to Life’. Our values of Transparency, Agility, Accountability, and Collaboration, hold us in good stead in every step of our patient journey. Numerous pharmaceutical, biotech, and biological products have been developed since the inception of BSV in 1971. We are driven by the goal of improving health and saving lives, through our innovative treatments and cures for patients across the globe. We do this in the critical therapeutic areas of women’s health, critical care, and IUI-IVF.
One of India’s leading biopharmaceutical companies, we keep the patient at the center of all our endeavors, and work towards widening accessibility of our products to reach patients and deliver positive outcomes. Our dedicated Research & Development center in Mumbai houses 60+ scientists who work tirelessly in finding new treatments that address unmet medical needs.
Business
BSV has pioneered many firsts
in hard to make pharmaceutical segments.
Therapy Areas
BSV is proud to have a wide range of product offerings that address the reproductive health challenges of women across ages. Some of the medical conditions include infertility, Rh incompatibility, endometriosis, PCOS, post-partum haemorrhage, luteal deficiency, etc.
The term ‘women’s health’ is a wide arena and covers anything from endometriosis to pregnancy and infertility. We see it as a comprehensive strategy to address key issues in this ecosystem.
The World Health Organization (WHO) defines it as the inability to conceive after at least a year of attempting without the use of contraception. After six months of attempting to conceive, a couple with a woman over the age of 35 should visit a doctor.
The GMP (Good Manufacturing Practices) Certification of our antibiotics, antifungals, and volume expanders guarantees excellent levels of efficacy against challenging situations like burns, diabetic ulcers, etc.
If not identified and treated immediately, sepsis is a fatal systemic disease caused by an imbalanced host response to infection. It can cause multiple organ failure and death.
Press Release
Mankind Pharma Completes Landmark Acquisition of BSV
New Delhi, October 23, 2024
Mankind Pharma Limited has completed the transaction to acquire 100% stake in BSV, for a purchase consideration of INR 13,768 Crores. This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women’s health and fertility drug market alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms.
Nexobrid: A revolutionary treatment for burns to treat patients in few hours
Feb 24, 2024
BSV, a biopharmaceutical company in India, has recently inked an exclusive distribution agreement with MediWound (NASDAQ: MDWD) to introduce NexoBrid, a groundbreaking treatment for severe…
NABICON 2024 focuses on novel treatments like NexoBrid for burn management
Feb 19, 2024
The National Academy of Burns organized the NABICON 2024 at Ranchi was held from February 15 to 17 to explore the recent advances in all aspects of burn prevention, burn wound management, burn reconstruction, rehabilitation and research….
BSV, FOGSI collaborate to increase breastfeeding, post-partum care awareness through RISHTA 2024 initiative
Feb 7, 2024
The initiative focuses on two formats of training: One programme focuses on educating medical practitioners through the ‘Train the Trainer’ programme and will run as a pilot in six cities in its first phase…
Re-Pharma Summit 2024: Revamping India’s pharma supply chains for resilience
Feb 2, 2024
The panel discussion, titled ‘From Manufacturing to Patient: Ensuring Seamless Pharma Supply Chains in India’, explored the complexities faced during the COVID-19 pandemic, the critical need for the availability of essential…
